Clinical trials: Bladder Cancer Treatment
Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation maintenance therapy works after cisplatin-based chemotherapy and surgery in treating patients with high-risk bladder cancer.
- Trial name
- NCT02718742
- Testing
- Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Mayo Clinic
Muscle Invasive Bladder Cancer, Molecular Taxonomy
Basal Like Bladder Cancer : Signature and Therapeutic
Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and no target therapies for this pathology are currently validated.
- Trial name
- DIATRIBBE (NCT02648100)
- Testing
- biomarker study
- Where
- France
- Volunteers
- 911 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Carcinoma, Colorectal Adenocarcinoma
Vaccine Response With NT-I7
Background: People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer.
- Conditions
- Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
- Trial name
- NCT04054752
- Testing
- Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments.
- Trial name
- GUB-BCR-001 (NCT03413982)
- Testing
- Registry
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center
Urothelial Cancer, Bladder Cancer
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
This study will evaluate the safety and efficacy of the combination of ABI-007, carboplatin and gemcitabine in the treatment of patients with advanced bladder cancer.
- Trial name
- NCT00995488
- Testing
- ABI-007 (Abraxane®)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Invasive Bladder Cancer Stage IV
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced bladder cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02863913
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Where
- China
- Sponsor
- Peking University
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Transitional Cell Carcinoma of the Bladder, Biomarkers
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic characterization will be explored in urothelial cancer patients treated with second-line treatment with pembrolizumab.
- Trial name
- RESPONDER (NCT03263039)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Muscle-invasive Bladder Cancer
Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored.
- Trial name
- NCT07440901
- Testing
- Immunotherapy plus chemotherapy
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer, Breast Cancer
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion.
- Conditions
- Cancer, Breast Cancer, Gastric Cancer, Renal Cancer
- Trial name
- ONCOPRO (NCT03787056)
- Testing
- Blood draws
- Where
- 17 sites in France
- Volunteers
- 410 people
- Sponsor
- Hospices Civils de Lyon
Ureteral Cancer, Urothelial Cancer
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.
- Conditions
- Ureteral Cancer, Urothelial Cancer, Bladder Cancer
- Trial name
- NCT03474107
- Testing
- Enfortumab Vedotin, Docetaxel, Vinflunine
- Where
- 158 sites in United States, Argentina and 17 more
- Volunteers
- 608 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Bladder Cancer, Urothelial Carcinoma
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
- Trial name
- NCT05524545
- Testing
- Evorpacept, Enfortumab Vedotin
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- ALX Oncology Inc.
Non-muscle Invasive Bladder Cancer
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.
- Trial name
- NCT07206225
- Testing
- PF-08052667, Sasanlimab, BCG
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 294 people
- Sponsor
- Pfizer
Lung Cancer, Breast Cancer
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps.
- Conditions
- Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer
- Trial name
- SkinHealth (NCT05878964)
- Testing
- EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Urothelial Carcinoma, Bladder Cancer
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and overall survival (OS) in patients…
- Trial name
- PemCab (NCT03534804)
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Utah
Non Muscle Invasive Bladder Cancer
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
This study is a prospective randomized open labeled dose ranging comparative study. Twenty four (24) patients with NMIBC who meet the inclusion/exclusion criteria will be recruited for the study following the initial diagnostic…
- Trial name
- NMIBC TURBT HG (NCT01799499)
- Testing
- TC-3 hydrogel
- Where
- Israel
- Sponsor
- UroGen Pharma Ltd.
Bladder Cancer
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the…
- Trial name
- NCT01094964
- Testing
- BCG solution, recombinant interferon alfa, epirubicin hydrochloride
- Where
- 9 sites in United Kingdom
- Volunteers
- 242 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Recurrent Bladder Cancer, Stage I Bladder Cancer
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
- Conditions
- Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00003167
- Testing
- Ad5CMV-p53 gene
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)